NCT06953518

An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Qualia Life Sciences · Industry
• Sex: All
• Age: 45 Years – 79 Years
• Healthy volunteers: Accepted

Summary

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

Detailed description

Objectives Within-group changes in outcomes will be compared from baseline to the end of the study period. Primary Outcome Measures: Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA) Secondary Outcome Measures: Remaining biomarkers in the Olink Target 48 Cytokine panel 36-Item Short Form Health Survey (SF-36) Frailty Index for Elders (FIFE) Depression Anxiety Stress Scale-21 (DASS-21) Side effect profile including: Number, type, severity, causality, and outcome of adverse events or unanticipated problems Symptoms of aging, assessed by: Aging Male Symptom scale Aging Female Symptom scale Participant Details: Study Duration per Participant: 7 days Total Number of Participants: 40

Conditions

• Inflammation

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Qualia Senolytic	Qualia Senolytic manufactured by Qualia Life Science

Timeline

• Start date: 2025-05-12
• Primary completion: 2025-05-18
• Completion: 2025-05-18
• First posted: 2025-05-01
• Last updated: 2025-05-01

Locations

1 site across 1 country: United States